MRNA · 8-K · 20260930PR408289

Manufacturing And Capacity

Moderna, Inc. · 2026-09-30 · Importance 31 · Surprise 42

Moderna’s manufacturing footprint has been transitioned to support an endemic vaccine market. The company also advanced manufacturing capabilities in the UK, Canada and Australia and established a manufacturing model to support intismeran autogene. The release describes these operational changes but provides no capacity or utilization figures.

Key facts

• Jerh Collins established the manufacturing model to support intismeran autogene. source
• As Chief Operating Officer, Juan Andres will work across Moderna to drive focus, prioritization and execution while leading the manufacturing organization. source
• During his tenure, Juan Andres led the build-out and scale-up of Moderna’s manufacturing capabilities, including rapid expansion of its global manufacturing network to support production and supply of its COVID-19 vaccine. source
• During Jerh Collins’s tenure, he helped transition Moderna’s manufacturing footprint for an endemic vaccine market and advanced manufacturing capabilities in the UK, Canada and Australia. source